Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | Insights into the Phase II TIDAL study

Tycel Phillips • 29 Sep 2022
SOHO 2022
Follicular Lymphoma Lymphoma Marginal Zone Lymphoma Non-Hodgkin Lymphoma Antibodies Bendamustine Rituximab Zandelisib
COASTAL TIDAL

Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the Phase II TIDAL study (NCT03768505), which is evaluating the safety and efficacy of zandelisib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL) who have failed at least two prior lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tycel Phillips

0:51
An update from ASH 2023: advancements in NHL treatment
Tycel Phillips • 10 Dec 2023
1:54
A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma
Tycel Phillips • 10 Dec 2023
1:55
Optimal sequencing of CAR-T and bispecifics in NHL
Tycel Phillips • 10 Dec 2023
1:17
GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL
Tycel Phillips • 10 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals